Hemostemix gains Bahamas approval; launches private placement for VesCell funding
Hemostemix received full Bahamas LARTA approval for VesCell Phase 1, advancing its regenerative-medicine program. The company also launched a non-brokered private placement for up to C$1 million, with initial close of C$380,500. It plans a longevity-focused VesCell protocol while canceling a CytoImmune license, highlighting near-term funding and execution risks.
View signal analysis